MedTrace Logo

Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)

NCT07706530 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-07-16

No results posted yet for this study

Summary

Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks

Conditions

  • Arthritic Psoriasis

Interventions

DRUG

CBP-0276 capsules 100mg

capsule with CBP-0276 powder

DRUG

Placebo

Capsule with placebo for CBP-0276

Sponsors & Collaborators

  • Clarent Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Diana Gómez Marin, MD · Innovación y Desarrollo en Ciencias de la Salud SRL de CV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-02-28
Completion
2027-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706530 on ClinicalTrials.gov